Gastrointestinal system, COVID-19 and potential mechanisms associated with coagulopathy

Curr Drug Targets. 2022 Sep 22. doi: 10.2174/1389450123666220922095913. Online ahead of print.ABSTRACTSARS-CoV-2 is a novel coronavirus expanded worldwide, generating a pandemic of acute respiratory syndrome called "coronavirus disease 2019" (COVID-19), which resulted in a global health crisis. The spectrum of COVID-19 manifestations ranges from none or mild symptoms to severe respiratory failure associated with systemic manifestations, mostly gastrointestinal symptoms. Hypercoagulability is an important feature of COVID-19 disease, which can potentially influence patients' prognosis. Therefore, gastroenterologists should focus on subjects with concomitant hypercoagulable gastrointestinal disorders as they may display a higher risk of thrombotic complications during SARS-CoV-2 infection. The aim of this review is to summarize the available evidence regarding the interplay of the prothrombotic pathogenetic mechanisms of both COVID-19 and hypercoagulable digestive diseases and the possible clinical implications. We summarized the potential interplay of prothrombotic mechanismsof both COVID-19 and hypercoagulable digestive diseases in the graphical abstract.PMID:36154571 | DOI:10.2174/1389450123666220922095913
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Source Type: research